Connor, Clark & Lunn Investment Management (CC&L)’s Acceleron Pharma XLRN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,325	Closed	-$425K	–	1140
2020 Q4	$425K	Buy	+3,325	New	+$390K	﹤0.01%	743
2015 Q2	–	Sell	-10,300	Closed	-$392K	–	681
2015 Q1	$392K	Sell	10,300 -3,600	-26%	-$143K	﹤0.01%	426
2014 Q4	$542K	Buy	+13,900	New	+$484K	﹤0.01%	379

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s XLRN Position: Q1 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Acceleron Pharma (XLRN) in Q1 2021, closing a stake of 3,325 shares — an estimated $425K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in XLRN in Q4 2014 and held it in 3 quarters. The position peaked at $542K in Q4 2014. 256 funds tracked by Wall St. Rank hold XLRN as of Q1 2021.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Acceleron Pharma position as of Q1 2021 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 3,325 Acceleron Pharma shares in Q1 2021, an estimated $425K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Acceleron Pharma in Q4 2014 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Acceleron Pharma position peaked at $542K in Q4 2014.
256 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2021, filed 13 May 2021.